BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Herrett E, Williamson E, Beaumont D, Prowse D, Youssouf N, Brack K, Armitage J, Goldacre B, MacDonald T, Staa TV, Roberts I, Shakur-Still H, Smeeth L. Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care. BMJ Open 2017;7:e016604. [PMID: 29197834 DOI: 10.1136/bmjopen-2017-016604] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Krishnamurthy A, Bradley C, Ascunce R, Kim SM. SAMSON and the Nocebo Effect: Management of Statin Intolerance. Curr Cardiol Rep 2022. [PMID: 35759168 DOI: 10.1007/s11886-022-01729-x] [Reference Citation Analysis]
2 Sydes MR, Barbachano Y, Bowman L, Denwood T, Farmer A, Garfield-Birkbeck S, Gibson M, Gulliford MC, Harrison DA, Hewitt C, Logue J, Navaie W, Norrie J, O'Kane M, Quint JK, Rycroft-Malone J, Sheffield J, Smeeth L, Sullivan F, Tizzard J, Walker P, Wilding J, Williamson PR, Landray M, Morris A, Walker RR, Williams HC, Valentine J; Data Enabled Trials Group Workshop Group members. Realising the full potential of data-enabled trials in the UK: a call for action. BMJ Open 2021;11:e043906. [PMID: 34135032 DOI: 10.1136/bmjopen-2020-043906] [Reference Citation Analysis]
3 Herrett E, Williamson E, Brack K, Perkins A, Thayne A, Shakur-Still H, Roberts I, Prowse D, Beaumont D, Jamal Z, Goldacre B, van Staa T, MacDonald TM, Armitage J, Moore M, Hoffman M, Smeeth L. The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs. Health Technol Assess 2021;25:1-62. [PMID: 33709907 DOI: 10.3310/hta25160] [Reference Citation Analysis]
4 Kristiansen O, Vethe NT, Peersen K, Fagerland MW, Sverre E, Jensen EP, Lindberg M, Gjertsen E, Gullestad L, Perk J, Dammen T, Bergan S, Husebye E, Otterstad JE, Munkhaugen J. Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side-effects: a randomized, double blinded crossover trial. Eur Heart J Cardiovasc Pharmacother 2020:pvaa076. [PMID: 32609361 DOI: 10.1093/ehjcvp/pvaa076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
5 Tudor K, Brooks J, Howick J, Fox R, Aveyard P. Tackling statin intolerance with n-of-1 trials (TaSINI) in primary care: protocol for a feasibility randomised trial to increase statin adherence. BMJ Open 2020;10:e033070. [PMID: 32051312 DOI: 10.1136/bmjopen-2019-033070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Drexel H, Coats AJS, Spoletini I, Bilato C, Mollace V, Perrone Filardi P, Rosano GMC. An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome. European Heart Journal - Cardiovascular Pharmacotherapy 2020;6:115-21. [DOI: 10.1093/ehjcvp/pvz079] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
7 Turner RM, Pirmohamed M. Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. J Clin Med 2019;9:E22. [PMID: 31861911 DOI: 10.3390/jcm9010022] [Cited by in Crossref: 54] [Cited by in F6Publishing: 63] [Article Influence: 18.0] [Reference Citation Analysis]
8 Chalmers I, Smeeth L, Goldacre B. Personalised Medicine Using N-of-1 Trials: Overcoming Barriers to Delivery. Healthcare (Basel) 2019;7:E134. [PMID: 31694150 DOI: 10.3390/healthcare7040134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Pedro-Botet J, Climent E, Benaiges D. Muscle and statins: from toxicity to the nocebo effect. Expert Opin Drug Saf 2019;18:573-9. [PMID: 31070941 DOI: 10.1080/14740338.2019.1615053] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
10 Taylor BA, Thompson PD. Statin-Associated Muscle Disease: Advances in Diagnosis and Management. Neurotherapeutics 2018;15:1006-17. [PMID: 30251222 DOI: 10.1007/s13311-018-0670-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
11 Gewandter JS, McDermott MP, He H, Gao S, Cai X, Farrar JT, Katz NP, Markman JD, Senn S, Turk DC, Dworkin RH. Demonstrating Heterogeneity of Treatment Effects Among Patients: An Overlooked but Important Step Toward Precision Medicine. Clin Pharmacol Ther 2019;106:204-10. [PMID: 30661240 DOI: 10.1002/cpt.1372] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
12 Galvin JE. Advancing personalized treatment of Alzheimer's disease: a call for the N-of-1 trial design. Future Neurology 2018;13:151-60. [DOI: 10.2217/fnl-2018-0004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]